N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=19 SGA-induced Metabolic Syndrome in Bipolar Youth
Bipolar Youth Treated With Second-generation Antipsychotics
Primary: Body Mass Index (BMI) — 24.4; 26.3 kg/m^2
Phase 3 N=40 The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder
Delayed Sleep Phase Syndrome
Primary: Change From Baseline Time of Dim Light Melatonin Onset (DLMO) at 4 Weeks — -1.23; -1.58 Hours — p=0.510
Phase 2 N=54 New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques
Carotid Artery Plaque
Primary: Number of Subjects Who Completed All of the Ultrasound Examinations — 17; 37 Participants
Phase 2 N=46 Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Bladder Cancer · Metastatic Transitional Cell Carcinoma
Primary: Number of Participants Who Were Progression Free at 2 Months — 23; 22 Participants
Phase 2 N=24 Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
Allergic Rhinitis · Allergic Rhinitis Due to Grass Pollen · Healthy Volunteers
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0; 0 Participants
N/A N=8 GE CVUS Device Evaluation
Echocardiography
Primary: Number of User Feedback Surveys — 1 Completed User Survey
Phase 2 N=11 Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
Total Parenteral Nutrition-induced Cholestasis
Primary: Number of Participants With Normalization of Direct Bilirubin — 11 participants
Phase 4 N=20 A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
Hand Dermatitis
Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale
Phase 4 N=28 The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO
E-Aminocaproic Acid · Bilateral Varus Rotational Osteotomy
Primary: Intraoperative Calculated Total Blood Loss — 535.7; 628.0 mL
Phase 3 N=624 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
HER-2 Positive Breast Cancer · Metastatic Neoplasm
Primary: Progression-free Survival (PFS) as Determined by Independent Radiological Review. — 5.8; 4.9 months — p=0.0334
Phase 3 N=526 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
Crohn's Disease
Primary: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 — 29.1; 49.5 percentage of participants — p=<0.0001
Phase 3 N=778 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
Systemic Lupus Erythematosus
Primary: Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib) — 45.6; 47.1 percentage of participants — p=0.711
N/A N=12 Aerosol Particle Concentrations Among Different Oxygen Devices for Spontaneous Breathing Patients With Tracheostomy
Transmission, Patient-Professional
Primary: Aerosol Particle Concentrations With Size of 1-3 Micrometer at 1 Foot Away From the Patient — 13000; 11000; 10000; 12000 particles/m3
Phase 2 N=18 Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
Edema, Pulmonary · Immersion · Diving
Primary: Number of Participants With Pulmonary Edema — 7; 9 Participants — p=0.317